Precigen (PGEN) Liabilities and Shareholders Equity (2012 - 2026)

Precigen (PGEN) has reported Liabilities and Shareholders Equity for 15 consecutive years, with $138.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 7.64% year-over-year to $138.6 million; the TTM figure through Mar 2026 stood at $567.3 million (up 31.72% YoY), while the FY2025 annual figure was $155.5 million, up 7.05% from the prior year.
• Liabilities and Shareholders Equity retreated to $138.6 million in Q1 2026 per PGEN's latest filing, from $155.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $335.6 million in Q1 2022 and bottomed at $73.2 million in Q2 2024.
• Historically, Liabilities and Shareholders Equity has averaged $179.7 million across 5 years, with a median of $155.5 million in 2025.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 64.75% — and 2025, when it soared 105.17%.
• Precigen's Liabilities and Shareholders Equity stood at $216.0 million in 2022, then slumped by 30.07% to $151.0 million in 2023, then dropped by 3.82% to $145.3 million in 2024, then advanced by 7.05% to $155.5 million in 2025, then retreated by 10.85% to $138.6 million in 2026.
• Business Quant data shows PGEN's Liabilities and Shareholders Equity at $138.6 million in Q1 2026, $155.5 million in Q4 2025, and $171.3 million in Q3 2025.